Joseph A. Markenson, MD

Appointments

Attending Physician, Hospital for Special Surgery

Professor of Clinical Medicine, Weill Medical College of Cornell University

Specialty
Rheumatology

Certification

Internal Medicine

Rheumatology

State Licensure
New York

Education

MD, 1970, State University of New York-Downstate Medical Center, New York, US

Residency

The New York Hospital, Weill Medical College of Cornell University - Internal Medicine, US

Joseph A. Markenson, MD is the author of the following articles on HSS.edu:

For Patients

• FDA Alert Regarding Lupus Medication: an HSS Rheumatology Perspective
• Special Report: Perspective on the recent data about celecoxib (Celebrex) and naproxen (Aleve)
• Bextra® Withdrawal from the Market - HSS Physicians Reflect on Options for Patients in Pain
• (Roche WA 180063) A Randomized, double-blind, placebo-controlled, parallel group study of the safety and reduction of signs and symptoms during treatment with Myeloma Receptor Antagonist (MRA)
• Hospital for Special Surgery Doctors Available to Comment on Withdrawal of Vioxx®
• A Double-Blind, Randomized Trial of Intra-Articular injections of 20 mg of Hyalgan® for the Treatment of Knee Pain Due to Osteoarthritis (Three-injection regimen Efficacy and Duration-20 mg/2ml Dose: Tread-20): Sanofi Protocol #L-9385
• An HSS Response to “Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies: A systemic review and meta-analysis of rare harmful effects in randomized controlled trials”
• COX-2 Inhibitor Safety: HSS Physicians Reflect on the Recommendations of the FDA Advisory Panel
• An In-Depth Overview of Osteoarthritis
• Progressive Multifocal Leukoencephalopathy (PML) in Two Lupus Patients Treated with Rituximab (Rituxan): An HSS Rheumatology Perspective
• Rheumatoid Arthritis & Tumor Necrosis Factor Therapy: Is it Right for You?

For Professionals

• FDA Alert Regarding Lupus Medication: an HSS Rheumatology Perspective
• Combining a Biologic Agent with Methotrexate in the Treatment of RA: Recent Advances
• Special Report: Perspective on the recent data about celecoxib (Celebrex) and naproxen (Aleve)
• Bextra® Withdrawal from the Market - HSS Physicians Reflect on Options for Patients in Pain
• (Roche WA 180063) A Randomized, double-blind, placebo-controlled, parallel group study of the safety and reduction of signs and symptoms during treatment with Myeloma Receptor Antagonist (MRA)
• An HSS Response to “Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies: A systemic review and meta-analysis of rare harmful effects in randomized controlled trials”
• COX-2 Inhibitor Safety: HSS Physicians Reflect on the Recommendations of the FDA Advisory Panel
• Progressive Multifocal Leukoencephalopathy (PML) in Two Lupus Patients Treated with Rituximab (Rituxan): An HSS Rheumatology Perspective
• An In-Depth Overview of Osteoarthritis

Special Expertise

Rheumatoid arthritis

Osteoarthritis

Systemic lupus erythematosus

Awards

Lupus Erythematosus Foundation Fellow, 1975-76

Diplomate, American Board of Internal Medicine, 1976

Diplomate, American Board of Internal Medicine, 1978

Affiliations

Subspecialty Board of Rheumatology, Member

Selected Publications

  

For more publications, please see the PubMed listing.

Clinical Trials

• (Roche WA 180063) A Randomized, double-blind, placebo-controlled, parallel group study of the safety and reduction of signs and symptoms during treatment with Myeloma Receptor Antagonist (MRA)
• A Double-Blind, Randomized Trial of Intra-Articular injections of 20 mg of Hyalgan® for the Treatment of Knee Pain Due to Osteoarthritis (Three-injection regimen Efficacy and Duration-20 mg/2ml Dose: Tread-20): Sanofi Protocol #L-9385
• CORRONA Data Collection Program
• (Roche WA 180062) A Randomized, double-blind, placebo-controlled, parallel group study of the safety and reduction of signs and symptoms during treatment with Myeloma Receptor Antagonist (MRA)